Evidence map›Paper›PMID 18703605›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2008

Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET.

Giuseppe Esposito, Giampiero Giovacchini, Jeih-San Liow, Abesh K Bhattacharjee, Dede Greenstein, Mark Schapiro, Mark Hallett, Peter Herscovitch, William C Eckelman, Richard E Carson and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 180 citations in OpenAlex.

  1. Trial
  2. Trial
  3. The utility of (11)C-arachidonate PET to study in vivo dopaminergic neurotransmission in humans.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2012
    Trial
  4. Trial
  5. A perspective: PLA2G4A as drug target for vascular inflammation in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  6. Article
  7. Article
  8. Effects of APOE4 on omega-3 brain metabolism across the lifespan.Trends in endocrinology and metabolism: TEM · 2024
    Review
  9. Arachidonic Acid Mobilization and Peroxidation Promote Microglial Dysfunction in Aβ Pathology.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Nutritional metabolism and cerebral bioenergetics in Alzheimer's disease and related dementias.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Review
  16. Review
  17. PET molecular imaging for pathophysiological visualization in Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2023
    Review
  18. Review
  19. Radiosynthesis of 20-[Prostaglandins, leukotrienes, and essential fatty acids · 2022
    Article
  20. Article

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Giuseppe EspositoBrain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892, USA.
Giampiero Giovacchini
Jeih-San Liow
Abesh K Bhattacharjee
Dede Greenstein
Mark Schapiro
Mark Hallett
Peter Herscovitch
William C Eckelman
Richard E Carson
Stanley I Rapoport
National Institutes of Health · USCincinnati Children's Hospital Medical Center · USInstitute on Aging · US

Funding

Pathophysiology of Basal Ganglia DisordersZ01NS003031 · NINDS · NEUROLOGICAL DISORDERS AND STROKE · PI HALLETT, MARK · 2007 to 2008
$4.4M
Brain Imaging In Human Aging, Alzheimer Disease And Other DisordersZIAAG000148 · NIA · NATIONAL INSTITUTE ON AGING · PI RAPOPORT, STANLEY I. · 2009 to 2016
$1.4M
Brain Imaging In Human Aging and Alzheimers DiseaseZ01AG000148 · NIA · NATIONAL INSTITUTE ON AGING · PI RAPOPORT, STANLEY I. · 2001 to 2008
$241k
Intramural NIH HHS Z01 AG000148
6 · The paper itself

Abstract

unlabelledIncorporation coefficients (K*) of arachidonic acid (AA) in the brain are increased in a rat model of neuroinflammation, as are other markers of AA metabolism. Data also indicate that neuroinflammation contributes to Alzheimer's disease (AD). On the basis of these observations, K* for AA was hypothesized to be elevated in patients with AD.

methodsA total of 8 patients with AD with an average (+/-SD) Mini-Mental State Examination score of 14.7+/-8.4 (mean age, 71.7+/-11.2 y) and 9 controls with a normal Mini-Mental State Examination score (mean age, 68.7+/-5.6 y) were studied. Each subject received a (15)O-water PET scan of regional cerebral blood flow, followed after 15 min by a 1-(11)C-AA scan of regional K* for AA.

resultsIn the patients with AD, compared with control subjects, global gray matter K* for AA (corrected or uncorrected for the partial-volume error [PVE]) was significantly elevated, whereas only PVE-uncorrected global cerebral blood flow was reduced significantly (P<0.05). A false-discovery-rate procedure indicated that PVE-corrected K* for AA was increased in 78 of 90 identified hemispheric gray matter regions. PVE-corrected regional cerebral blood flow, although decreased in 12 regions at P<0.01 by an unpaired t test, did not survive the false-discovery-rate procedure. The surviving K* increments were widespread in the neocortex but were absent in caudate, pallidum, and thalamic regions.

conclusionThese preliminary results show that K* for AA is widely elevated in the AD brain, particularly in regions reported to have high densities of senile (neuritic) plaques with activated microglia. To the extent that the elevations represent upregulated AA metabolism associated with neuroinflammation, PET with 1-(11)C-AA could be used to examine neuroinflammation in patients with AD and other brain diseases.

Indexed as

Arachidonic AcidAgedAged, 80 and overAlzheimer DiseaseBrainCarbon RadioisotopesEncephalitisFemaleHumansIsotope LabelingMaleMiddle AgedPositron-Emission TomographyRadiopharmaceuticalsReproducibility of ResultsSensitivity and SpecificityArachidonic AcidCarbon RadioisotopesRadiopharmaceuticals

Identifiers

PMID18703605
PMCPMC2587283
OpenAlexW2120095464

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.